Bloating — Body Handbook

Gut · §53

Bloating

Bloating is not usually too much gas. Imaging shows that in most cases the total amount of gas in the gut is barely different from someone without symptoms — the belly pushes out because the diaphragm drops and the abdominal wall relaxes, and the brain reads normal volumes as painful pressure. That's why "burp it out" advice misses, and why the things that actually work are dietary, microbial, and neurological rather than the usual anti-gas remedies.

Respond · As-needed Evidence Moderate Chapter Gut

Bloating affects somewhere around one in five adults at any moment, and twice as many women as men Sandler et al. 2000. For most people, a short structured workup plus a 2–6 week dietary trial settles it, with cheap tools (an app, peppermint oil, maybe a dietitian visit) doing most of the work. The harder part is staying off the indefinite elimination diet that wellness culture pushes — long-term restriction has its own costs. The catch worth saying up front: a small set of warning signs (persistent symptoms over 50, weight loss, blood, nighttime waking, family history of GI cancer) takes this entirely out of self-management and into a clinic.

Two separate things happen and most people lump them together. Bloating is the feeling — pressure, fullness, the sense that your belly is about to give. Distension is the measurable thing — your waistband actually gets tighter. They often dissociate. You can feel severely bloated with no real girth change, and your stomach can push out three centimetres without you minding much Houghton et al. 2006.

When the belly does push out, it's usually not because more gas suddenly arrived. CT imaging of patients during a bloating episode shows the diaphragm drops about a centimetre, the front abdominal wall relaxes, and the gut contents redistribute downward and forward — like squeezing a balloon from the top. Girth increases. Gas volume doesn't Accarino et al. 2009. The motor pattern is backwards: a healthy gut contracts the abdominal wall and pushes the diaphragm up to compress contents. A bloated gut does the opposite, and pushes them out into visible distension.

The other half is perception. The bowel is full of nerves; normal volumes of normal contents send signals upstairs constantly, and a healthy nervous system filters most of them out. In bloated patients those signals come through louder — visceral hypersensitivity. The same gas that doesn't register in a control feels like a tight band in the IBS patient. This is why fixing the symptom isn't about removing gas; it's about quieting the muscle pattern and the nerves.

What does add real gas, when there's real gas: FODMAPs. These are short-chain carbohydrates — fructose in apples, lactose in milk, fructans in wheat and onion, polyols in stone fruit and sugar-free gum — that the small intestine doesn't fully absorb. They reach the colon intact, the bacteria living there ferment them, and the byproducts are hydrogen, methane, carbon dioxide, and an osmotic pull of water into the lumen Staudacher and Whelan 2017. Now there's actual distension to be hypersensitive to.

What's actually been shown to work

For functional bloating — meaning the kind that isn't a sign of something more serious, which is most of it — four interventions have real trial backing.

The 2021 American College of Gastroenterology guideline gives a conditional recommendation for trying a low-FODMAP diet, and the same guideline conditionally recommends two other things: enteric-coated peppermint oil and a 2-week course of rifaximin, a gut-selective antibiotic Lacy et al. 2021. Peppermint oil works by blocking calcium channels in intestinal smooth muscle — same family as some prescription antispasmodics, but cheaper and OTC. Pooled across 9 trials it more than doubled the chance of symptom improvement Khanna et al. 2014.

The most surprising entry on the list is gut-directed hypnotherapy. The relabel — bowel hypnotherapy delivered by a specialist trained in the protocol, not a stage hypnotist — clears one of the highest effect sizes in functional gut medicine, with number needed to treat around four Ford et al. 2014. Low-dose tricyclic antidepressants like amitriptyline at 10–25 mg at night belong in the same family of "the brain runs more of the gut than people think" treatments and have a similar evidence base Black et al. 2020.

What hasn't quite earned its reputation: probiotics. The pooled meta-analytic signal is mildly positive, but the literature mixes dozens of different strains at different doses and most commercial products contain none of the specific strains that were studied. The same 2021 ACG guideline actually recommends against them as a class because of this inconsistency Ford et al. 2018, Lacy et al. 2021.

When to stop self-managing and see a doctor

Most bloating is functional and safe to work on at home. A short list of features moves the situation into "see a doctor first, then maybe come back to this protocol." These are the red flags the gastroenterology guidelines name Lacy et al. 2016:

For women specifically, there's one more pattern worth knowing. Persistent bloating most days for more than two or three weeks, especially when it shows up with early fullness after small meals, pelvic discomfort, or new urinary urgency, is part of the ovarian cancer presentation pattern. In Goff's symptom-index work, 89% of women with early-stage ovarian cancer had this cluster in the year before diagnosis Goff et al. 2007. The base rate is low — most women with these symptoms don't have ovarian cancer — but it's high enough that the workup (a CA-125 blood test and a transvaginal ultrasound) is worth doing if the pattern fits.

Two specific things to test for before assuming functional bloating, especially if symptoms have been going on for months:

Celiac disease — a blood test called tTG-IgA, sensitivity around 95%, done before you cut gluten (the test relies on the immune response that disappears when you stop eating gluten). Global prevalence is roughly 0.7–1.4% and it's chronically underdiagnosed Singh et al. 2018.
Lactose intolerance — either a hydrogen breath test or a two-week withdrawal trial. Prevalence depends heavily on ancestry, from around 5% in northern European populations to ~90% in East Asian and West African populations Misselwitz et al. 2019.

What persistent bloating actually costs

If you've had it for months, you already know some of this. The waistband decision in the morning. The shirt that hung straight at 8 a.m. and doesn't by 2 p.m. The lunch you skip because last week's lunch wrecked the afternoon. Friends start using the same vocabulary you do — "are you feeling okay today?" — in the same voice they'd use for a hangover.

The harder cost is the one you don't notice taking. International surveys of IBS patients — bloating is the dominant symptom in around 80% of them — found patients would, on average, give up 25% of their remaining life expectancy to be symptom-free, and 14% said they'd accept a 1-in-1,000 monthly risk of death for a cure Drossman et al. 2009. That's the same willingness-to-risk profile measured in advanced cancer patients. People who haven't lived with it underestimate this; people who have, don't.

Day to day, the second-order effects compound. The post-meal slump bleeds into focus. The sleep onset is worse when nighttime distension is bad. The intimacy-avoidance is real and rarely discussed. Most cohorts report 2–3 missed workdays a month at the severe end Sandler et al. 2000. And the gut-brain axis runs both ways: chronic bloating drives anxiety and low mood, and anxiety amplifies how much the gut signals — which is why hypnotherapy and low-dose antidepressants work on the symptom and not just the mood. The version of you that stops planning your day around your stomach is a different version of you.

The order that actually works

Once the red-flag list is clear, the evidence-backed ladder runs roughly five rungs. Most people don't need all of them. Most people need the first two.

A few free habits sit underneath the whole ladder, worth checking before you touch your diet. Constant grazing never lets the gut's between-meal cleanup wave run; wolfing food half-chewed and eating hunched and rushed each nudge bloating on their own. None of it costs anything to fix, and for some people it's most of the answer.

Make sure you're not constipated. Slow transit gives gas more time to build up; treating the constipation alone often resolves the bloating. Adequate hydration, ramped-up soluble fibre (psyllium tolerated better than wheat bran in IBS), and an osmotic laxative if needed.
Run a structured low-FODMAP trial. 2 to 6 weeks of strict elimination, then methodical reintroduction one food family at a time. Use a dietitian or the Monash University FODMAP app — both work; doing it from a random blog post usually fails. The reintroduction phase is mandatory, not optional. Strict elimination is not meant to be permanent.
Add enteric-coated peppermint oil at 180–225 mg three times daily before meals. OTC, ~$15–25 a month.
If symptoms persist, ask about a rifaximin trial. 550 mg three times daily for two weeks. Prescription. Particularly worth raising if bloating is your dominant symptom and you have diarrhoea-predominant IBS — that's the population in the approval trial.
Bring in the gut-brain layer. Gut-directed hypnotherapy with a trained practitioner, or low-dose amitriptyline 10–25 mg at night, especially if bloating overlaps with pain or visceral sensitivity is the driver.

What most guides get wrong

"It's trapped gas." Mostly not. The amount of gas in a bloated gut and a calm gut, measured directly, is similar Accarino et al. 2009. This is why simethicone, anti-gas drops, and "let it out" advice underperform — they target the wrong variable.

"Cut carbs and it'll go away." A subset of people respond dramatically to FODMAP restriction. That's not the same as everyone needing to cut every fermentable carbohydrate forever. The diet was designed as a diagnostic tool: eliminate, reintroduce, identify your specific triggers, eat normally otherwise Staudacher and Whelan 2017. Long-term blanket restriction reshapes the gut microbiome in ways nobody is sure are good.

"It's gluten." Real celiac disease is real and worth testing for. Non-celiac gluten sensitivity is a more contested category — when researchers run blinded challenges, many people who report gluten sensitivity turn out to be reacting to fructans (a FODMAP), which happen to be abundant in wheat Catassi et al. 2013. The practical implication: test for celiac with a blood test first, then trial a structured FODMAP elimination second, before concluding gluten is the variable.

"SIBO explains everything." Small intestinal bacterial overgrowth — and its methane-producing cousin — is a real phenomenon and rifaximin works on it. But hydrogen breath testing has imperfect specificity, the cutoffs and substrates remain methodologically contested, and the wellness-economy version of SIBO has expanded far past what the evidence supports. The ACG SIBO guideline recommends testing only when pretest probability is reasonable Pimentel et al. 2020.

"A probiotic will fix it." Some patients respond to specific strains at specific doses. The drugstore "digestive health" bottle almost certainly doesn't contain those, and the studied strains aren't interchangeable. The 2021 ACG guideline recommends against probiotics for IBS as a class for exactly this reason Lacy et al. 2021.

Who this hits differently

Women have roughly twice the prevalence of men Sandler et al. 2000. Premenstrual worsening is consistent and real — progesterone slows gut motility in the luteal phase and visceral nerves get more sensitive as estrogen drops. If bloating tracks your cycle, that's expected and treatable with the same protocol, sometimes with timed FODMAP awareness in the second half of the month. Two more things worth knowing as a woman specifically: persistent bloating most days for over two or three weeks with early fullness or new urinary urgency warrants the ovarian-cancer workup mentioned earlier Goff et al. 2007; and pelvic floor dysfunction can drive both constipation and bloating, so if straining or incomplete evacuation is part of the picture, a pelvic floor physical therapist often beats more diet changes.

Past 60, the rules tighten. The chance that bloating represents something organic — colon cancer, ovarian cancer, structural disease, gastroparesis — rises enough that "new bloating in someone over 50, especially new in someone over 60" is itself a workup trigger Lacy et al. 2016. Don't run the self-management protocol first. Get the colonoscopy, the imaging if indicated, and the structural causes ruled out before assuming it's functional.

Why people try this and don't improve

Staying on strict low-FODMAP forever. By far the most common failure. The diet quiets symptoms, the patient is afraid to reintroduce, three months pass, the gut microbiome shifts, and now everything feels like a trigger. Reintroduction is harder the longer you wait. Two to six weeks of elimination, then structured reintroduction, full stop.

Skipping the constipation evaluation. Slow transit is one of the more common drivers of bloating and one of the more treatable. People go straight to elimination diets without checking whether they're moving daily, and miss the simpler answer.

Throwing OTC anti-bloat products at it. Simethicone, charcoal, "digestive enzyme" stacks. The mechanism mismatch means most underperform their marketing. Worse, they let serious causes hide while the patient self-treats for months.

Chasing repeated SIBO courses. One rifaximin trial is reasonable in the right phenotype. A pattern of repeated empirical antibiotic courses without diagnostic discipline usually means the bloating isn't primarily microbial and the protocol needs to widen toward the gut-brain rungs.

Treating it as purely physical. The visceral hypersensitivity layer is real and quieting it changes the symptom even when the gas, the transit, and the diet haven't changed. Patients who try every diet and supplement for years before considering hypnotherapy or a low-dose tricyclic are usually surprised by how much that last step did Ford et al. 2014.

What changes when it lifts

The first thing most people notice is the afternoon they didn't lose. Lunch goes in, and an hour later they're working instead of waiting. Within 2–4 weeks of a properly run low-FODMAP trial, 50–80% of responders see a clinically meaningful drop in symptoms Halmos et al. 2014, Staudacher and Whelan 2017. For rifaximin responders the typical benefit lasts about ten weeks per course, and the medication keeps working on re-treatment Pimentel et al. 2011.

By month two or three, the waistband decision in the morning stops being a decision. The friend who'd started asking how you were feeling stops asking. The intimacy avoidance fades. Sleep onset improves on the nights where nighttime distension was the culprit. The lunch you'd been skipping — or eating in nervous anticipation — turns into a meal again.

By a year, the real win is that the relationship to food is back. You know your specific triggers, you can have onion at the dinner party and adjust, the diet isn't a fortress. The catch worth saying: this isn't always permanent. Symptoms recur, especially under stress, after antibiotics, around the cycle. The protocol becomes a thing you know how to run when you need it, not a thing you live inside.

If an organic cause was found — celiac, a lactose intolerance you didn't know about, gastroparesis, anything structural — the change can be sharper still. Cutting gluten in real celiac disease often eliminates the symptom entirely within months, with the bonus of preventing the longer-term complications of untreated disease.

Related worth knowing about

Adjacent topics this entry brushes against but doesn't cover end to end: full management of irritable bowel syndrome (this entry covers the bloating slice); the constipation entry, which is often the first thing to check; the broader gut microbiome and what we know about feeding it; pelvic floor dysfunction, which drives a meaningful subset of bloating in women and isn't a diet problem; and gut-directed hypnotherapy as its own intervention rather than the tail end of this protocol.

Related in the handbook

Helps

— When bloating tracks with IBS, a proper low-FODMAP run is the most reliable dietary fix.
— Wolfing food half-chewed is a common, fixable contributor to bloating.
— Before blaming a food for bloating, check how you're sitting and how fast you're eating.
— Constant snacking blocks the gut's cleanup cycle — spacing meals out is a free fix for some bloating.

— Backed-up stool is a common driver of bloating — clearing constipation often deflates it.
— Getting the fibre type wrong is a common, fixable bloating trigger: too much of the gassy kind backfires. Match the fibre to the symptom.
— Much of bloating is the brain misreading normal gut volume as painful pressure — a gut-brain loop.
— Bloating that comes with pain tied to your bathroom habits often turns out to be IBS.
— SIBO gets blamed for a lot of bloating; it's worth ruling in only if you have a genuine risk factor.
— A colonic won't fix bloating; the actual causes have safer, evidence-based fixes.
— Histamine intolerance is one of the lesser-known causes behind unexplained bloating.

Substance + claimed effects

Abdominal bloating is the subjective sensation of trapped gas, fullness, or abdominal pressure, often (but not always) accompanied by visible abdominal distension. Bloating and distension are distinct phenomena that frequently dissociate: patients can report severe bloating with no measurable girth change, and abdominal girth can increase without subjective bloating Houghton et al. 2006. Prevalence in the general adult US population is approximately 15–30%, with female-to-male ratios of roughly 2:1 Sandler et al. 2000. Bloating is the dominant symptom in functional gastrointestinal disorders: ~66–90% of patients with irritable bowel syndrome (IBS) report it, with similarly high rates in functional dyspepsia and chronic constipation Iovino et al. 2014, Lacy et al. 2016. This entry covers bloating holistically: functional drivers (visceral hypersensitivity, abdomino-phrenic dyssynergia, fermentable-carbohydrate intolerance, microbial overgrowth, slow transit), pathological drivers (celiac disease, lactose/fructose malabsorption, gastroparesis, ovarian/GI malignancy, ascites), red-flag features that warrant workup, dietary and pharmacological management, and downstream effects on quality of life, mood, and daily function.

Evidence by addressing question

Mechanism

Bloating is multifactorial; the modern model rejects the older "too much gas" view. Total intestinal gas volume in patients with functional bloating is, on average, only marginally increased over controls — the dominant abnormalities are visceral hypersensitivity (normal gas volumes perceived as painful or distending) and abdomino-phrenic dyssynergia, a paradoxical motor response where the diaphragm descends and the anterior abdominal wall relaxes in response to even modest intraluminal contents, redistributing them caudally and ventrally Accarino et al. 2009, Villoria et al. 2011. CT imaging during induced distension shows the diaphragm descends ~1 cm and the anterior abdominal wall protrudes while girth at the umbilicus increases ~3 cm — with no change in luminal gas volume Accarino et al. 2009.

Fermentation of poorly-absorbed short-chain carbohydrates (FODMAPs: fermentable oligo-, di-, monosaccharides and polyols) in the small intestine and proximal colon generates gas (hydrogen, methane, CO₂) and osmotically draws water into the lumen — distending the bowel and providing the substrate that hypersensitive patients perceive as bloating Staudacher and Whelan 2017. Slow colonic transit prolongs gas residence time and contributes in constipation-predominant phenotypes Houghton et al. 2006. Methane-producing archaea (Methanobrevibacter smithii) further slow transit, producing a self-reinforcing loop in methane-positive small intestinal bacterial overgrowth (now termed intestinal methanogen overgrowth, IMO) Pimentel et al. 2020.

Evidence

The strongest interventional evidence is for the low-FODMAP diet. The Monash group's randomized crossover trial in 30 IBS patients showed overall gastrointestinal symptom scores fell from 44.9 to 22.8 on a low-FODMAP diet versus a typical Australian diet (P<0.001), with bloating among the most-improved symptoms Halmos et al. 2014. A 2017 systematic review identified six RCTs and 16 comparative studies showing consistent ~50–80% responder rates for IBS symptoms, including bloating Staudacher and Whelan 2017. The 2021 ACG IBS guideline gives a conditional recommendation for the low-FODMAP diet as a limited trial (very low quality evidence per GRADE due to blinding limitations, but consistent effect) Lacy et al. 2021.

Rifaximin, a non-absorbed gut-selective antibiotic, was tested in the TARGET 1 and TARGET 2 trials (combined N=1,260): 550 mg three times daily for 2 weeks produced adequate relief of global IBS symptoms in 40.7% versus 31.7% on placebo (P<0.001), with similar magnitude effect specifically on bloating (40.2% vs 30.3%, P<0.001) Pimentel et al. 2011. FDA-approved for IBS-D in 2015. The 2021 ACG guideline gives a conditional recommendation, moderate-quality evidence Lacy et al. 2021.

Peppermint oil (enteric-coated, ~180–225 mg three times daily) showed pooled relative risk of symptom improvement of 2.23 (95% CI 1.78–2.81) across 9 RCTs (N=726); abdominal pain and bloating both responded Khanna et al. 2014. Mechanism is L-type calcium channel blockade in intestinal smooth muscle.

For abdomino-phrenic dyssynergia, a randomized trial of EMG-guided biofeedback (training patients to contract the abdominal wall and relax the diaphragm postprandially) reduced postprandial girth increase by ~75% and subjective bloating scores by ~half over 1 month versus sham Barba et al. 2015. Still niche — most centres don't offer it.

Probiotics: a 2018 meta-analysis of 53 RCTs (N=5,545) found a number-needed-to-treat of 7 for global IBS symptom improvement, but heterogeneity is severe and strain-specific data are weak; the ACG guideline gives a conditional against recommendation due to inconsistency Ford et al. 2018, Lacy et al. 2021. Antispasmodics (hyoscine, peppermint, dicyclomine) and gut-brain neuromodulators (low-dose tricyclics, SSRIs) showed consistent benefit in a network meta-analysis of 51 RCTs Black et al. 2020. Gut-directed hypnotherapy reaches NNT ~4 in specialist centres Ford et al. 2014.

Protocol

The first-line workup of chronic bloating in primary care: rule out red-flag features (see contraindications), screen for celiac with tissue transglutaminase IgA (sensitivity ~95%, specificity ~95%) Singh et al. 2018, consider lactose breath test or empirical lactose withdrawal in suggestive cases Misselwitz et al. 2019, and ensure adequate constipation management. For functional bloating without red flags, the evidence-based tier order: (1) trial of low-FODMAP diet for 2–6 weeks with structured reintroduction under dietitian guidance — full elimination is not meant to be permanent because of microbiome and nutritional consequences Staudacher and Whelan 2017; (2) enteric-coated peppermint oil 180–225 mg TID; (3) if symptoms persist, consider hydrogen/methane breath testing and a 2-week rifaximin course (550 mg TID) Pimentel et al. 2020, Lacy et al. 2021; (4) referral for gut-directed hypnotherapy or low-dose tricyclic (10–25 mg amitriptyline at night) when bloating overlaps with pain Ford et al. 2014, Black et al. 2020; (5) biofeedback for measured abdomino-phrenic dyssynergia at tertiary centres Barba et al. 2015.

Contraindications

The red-flag list — features that mandate workup and remove this from the self-management space: (1) new-onset bloating after age 50; (2) unintentional weight loss; (3) rectal bleeding, melena, or iron-deficiency anemia; (4) nocturnal symptoms waking the patient; (5) family history of colorectal cancer or inflammatory bowel disease; (6) progressive worsening rather than waxing-waning; (7) palpable mass or ascites Lacy et al. 2016. In women, persistent bloating (most days for >2–3 weeks) accompanied by early satiety, pelvic pain, or urinary urgency is part of the ovarian cancer symptom triad — Goff's index identified that 89% of women with early-stage ovarian cancer had these symptoms in the year prior to diagnosis, with positive predictive value ~1% in primary care but high enough to warrant CA-125 and transvaginal ultrasound Goff et al. 2007. Celiac disease prevalence is ~0.7–1.4% globally and remains underdiagnosed; tTG-IgA before any dietary trial avoids false negatives from a gluten-restricted diet Singh et al. 2018. Gastroparesis (delayed gastric emptying, often diabetic or post-viral) presents with early-satiety bloating and benefits from prokinetic management rather than FODMAP restriction.

Misconceptions

(a) "Bloating is excess gas." Mean total intestinal gas in bloated patients differs only modestly from controls; the abnormality is perception and abdominal-wall motor response, not gas volume Accarino et al. 2009, Villoria et al. 2011. (b) "Cutting carbs cures bloating." A subset benefits from FODMAP restriction, but the same diet starves beneficial bifidobacteria, reduces short-chain fatty acid production, and is not designed for long-term use; the reintroduction phase is mandatory Staudacher and Whelan 2017. (c) "Gluten is the problem." Non-celiac gluten sensitivity exists but is heterogeneous; many cases relabel as fructan intolerance (a FODMAP), since wheat is a major fructan source Catassi et al. 2013. (d) "SIBO is the answer to everyone's bloating." Hydrogen breath testing has imperfect specificity and over-diagnosis is real; ACG guidelines recommend it only when pretest probability is reasonable Pimentel et al. 2020. (e) "Probiotics fix it." Net signal is positive but heterogeneity is high and most commercial products lack the specific strains studied Ford et al. 2018.

Audience

Female-predominant: prevalence ~2× that in men across most studies, partly explained by hormonal modulation of visceral sensitivity (premenstrual worsening is consistent) and partly by undertreated constipation in women Sandler et al. 2000. Older adults (60+) require lower threshold for organic workup because the prior probability of malignancy and structural disease rises sharply. Athletes and endurance runners have a distinct presentation (exercise-induced bloating from splanchnic hypoperfusion) outside this entry's main scope. Pregnant readers should not initiate a strict elimination diet without obstetric and dietetic supervision.

Failure modes

Most common failure: indefinite strict low-FODMAP without reintroduction — symptoms relapse on re-exposure, microbiome diversity drops, the patient concludes "everything causes bloating" and over-restricts. Second: empirical OTC simethicone or "anti-bloat" supplements with no diagnostic step, masking a red-flag condition. Third: skipping the constipation evaluation — slow transit is a common, treatable driver of bloating Houghton et al. 2006. Fourth: chasing SIBO without proper testing and over-treating with repeated rifaximin courses. Fifth: anxiety-driven hypervigilance amplifying visceral perception, which is why gut-brain therapies (CBT, hypnotherapy, tricyclics) show among the highest effect sizes Ford et al. 2014.

Practicalities

Low-FODMAP requires structured education — a Monash-trained dietitian is the high-yield delivery model, charging ~$100–200 per session over 2–3 sessions. Smartphone app (Monash University FODMAP Diet) replicates much of the food-list work for ~$10 once. Enteric-coated peppermint oil capsules are OTC, ~$15–25/month. Rifaximin requires prescription and was historically expensive in the US (~$2,000 for a 14-day course) though Medicare and most US commercial plans now cover for IBS-D after 2015 FDA approval; far cheaper internationally. tTG-IgA blood test is routine and covered by most insurance. Breath testing for SIBO is ~$150–300 and not always insured. Biofeedback for abdomino-phrenic dyssynergia is available at fewer than 20 centres globally.

Stakes

Quality-of-life burden is substantial and underrecognized. International IBS surveys report patients giving up 25% of remaining life expectancy on average to be symptom-free, and 14% reporting they would accept a 1/1000 monthly mortality risk for a cure — comparable willingness-to-risk to advanced cancer patients Drossman et al. 2009. Bloating specifically correlates with lower social functioning, higher rates of depression and anxiety, missed workdays, and avoidance of intimacy. Untreated severe bloating averages 2–3 missed workdays per month in IBS cohorts Sandler et al. 2000.

Payoff

Functional bloating responds: in trials, 50–80% of patients on a properly delivered low-FODMAP diet achieve clinically meaningful improvement within 2–4 weeks Halmos et al. 2014, Staudacher and Whelan 2017. Rifaximin responders maintain benefit for ~10 weeks on average per 2-week course, with retreatment efficacy preserved Pimentel et al. 2011. Identifying and treating an actual driver (celiac, gastroparesis, IMO) can essentially eliminate the symptom rather than dampen it.

The credibility range

Optimist case

Bloating is now a well-mechanized symptom with multiple effective treatments. Two decades of high-quality work (Azpiroz, Whorwell, Gibson, Pimentel groups) replaced the "trapped gas" folk model with a mechanistic account combining visceral hypersensitivity, abdomino-phrenic dyssynergia, fermentable-carbohydrate intolerance, and microbial gas production. The low-FODMAP diet has multiple RCTs with consistent ~50–80% responder rates and is endorsed in major guidelines. Rifaximin is FDA-approved on the back of two pivotal trials with N>1,200. Peppermint oil meta-analysis is consistent and cheap. Gut-directed hypnotherapy has NNT in the 3–5 range — among the highest effect sizes in functional GI medicine. For functional bloating, today's evidence-based ladder will help the substantial majority of patients within months.

Skeptic case

Most bloating trials carry significant placebo magnitudes (30–40% response on inert arms) and blinding is intrinsically difficult for diets and breath-testable interventions. The 2021 ACG guideline rates low-FODMAP evidence as "very low quality" per GRADE despite the conditional recommendation. SIBO diagnosis remains methodologically contested — breath-test cutoffs, lactulose vs glucose substrate, and the concept's relationship to bacterial culture are unresolved, and rifaximin's mechanism may not be SIBO eradication at all. Probiotics' positive meta-analytic signal hides massive strain heterogeneity. Visceral hypersensitivity is real but its psychometric measurement (barostat distension thresholds) doesn't predict treatment response well. And bloating's overlap with depression/anxiety suggests at least some of the symptom is centrally mediated, raising whether peripheral treatments are aiming at the right target.

Author's call

This is a well-evidenced area with real, replicable interventions for the dominant functional phenotype, and a clear red-flag list for the pathological tail. The evidence rates 4/5 — multiple RCTs, network meta-analyses, current guidelines — short of 5 because effect sizes are modest, placebo responses are large, and GRADE assessments of even the headline interventions are conservative. Controversy is low-to-moderate (2/5): the dominant framework is consensus, but SIBO methodology, probiotic strain selection, and the boundaries of non-celiac gluten sensitivity remain contested. The right reader response is symptomatic and graduated: red flags first, then dietary trial, then targeted pharmacology, with gut-brain therapy for the persistent and hypersensitive end. This is an action-rich entry; readers walk away with a workable response protocol, not just understanding.

Stakeholder + incentive map

Commercial: the "anti-bloat" wellness market is enormous and largely unregulated — probiotic brands, "gut reset" cleanses, digestive enzyme stacks, charcoal capsules. Most products carry weak or absent evidence. The low-FODMAP ecosystem has its own commercial layer (Monash app, branded products, dietitian referrals) but with stronger evidence base. Rifaximin is Salix/Bausch-marketed and its US pricing has been a flashpoint. Professional: gastroenterology and dietetics own the established workup; pelvic floor physical therapy is an emerging discipline addressing dyssynergic defecation as a bloating driver. Cultural: the "bloating" frame in women's media has merged real GI symptoms with body-image anxiety, leading to over-restriction and disordered-eating overlap. The "leaky gut" and "candida" subcultures offer non-evidence-based bloating frameworks that compete for the same patient population. Skeptic-incentive: conventional GI consensus pushes back against SIBO over-diagnosis and against indefinite elimination diets; the dietetic profession increasingly emphasizes reintroduction.

Population variability

Female:male prevalence ~2:1; premenstrual worsening is common and biologically plausible (progesterone effects on motility, estrogen on visceral sensitivity) Sandler et al. 2000. Age stratification matters editorially: under 50 with no red flags, functional workup first; over 50 or with red flags, organic workup first. IBS-C (constipation-predominant) phenotypes have stronger gas-residence and methane-overgrowth correlations Houghton et al. 2006. Patients with comorbid anxiety/depression respond more to gut-brain treatments; those with overt fermentation patterns (post-prandial bloating, gas, audible borborygmi) respond more to FODMAP restriction. Lactose malabsorption prevalence varies enormously by ancestry — ~5% in northern European populations to ~90% in East Asian and West African populations Misselwitz et al. 2019. Celiac is most prevalent in those of European ancestry but global prevalence ~0.7% Singh et al. 2018.

Knowledge gaps

What's still unsettled: (1) the precise role and best test for SIBO/IMO — culture is impractical, breath testing has imperfect specificity, and the relationship to functional bloating is incompletely mapped Pimentel et al. 2020. (2) Which probiotic strains, at what doses, for which patient phenotype — meta-analyses pool too heterogeneous a literature. (3) The long-term microbiome consequences of repeated low-FODMAP cycling. (4) Whether biofeedback for abdomino-phrenic dyssynergia generalizes outside specialized centres. (5) The mechanistic boundary between "non-celiac gluten sensitivity," fructan intolerance, and pure nocebo. (6) Evidence that would change the call: high-quality double-blind dietary RCTs with placebo-matched comparators (technically difficult); cluster-randomized trials of structured dietetic-led FODMAP reintroduction with long-term outcomes; standardized SIBO diagnostic criteria with culture-validated breath-test cutoffs.

Scope coverage versus brief. Brief named four threads: dietary, motility, and microbial drivers; red flags warranting workup; and QoL effects. All four are covered end-to-end. Motility lives mostly in the mechanism section (abdomino-phrenic dyssynergia + slow transit) and the protocol step on constipation; microbial drivers in the evidence section (rifaximin, FODMAP fermentation) and misconceptions (SIBO over-diagnosis); red flags as a standalone contraindications section plus the over-60 audience scope; QoL in the stakes section with the Drossman willingness-to-trade data.

Hard scoping calls. Pelvic floor dysfunction (dyssynergic defecation) is a real driver of bloating in a subset, particularly women. Mentioned briefly under audience and forward-pointed in out-of-scope; declined to expand because it warrants its own entry — the diagnostic workup (anorectal manometry, balloon expulsion) and treatment (biofeedback by a pelvic floor PT) are substantial and don't fit cleanly inside "bloating." Flagged as a separate-entry candidate below. Similarly, full IBS management is referenced but not covered — bloating is the symptom slice, IBS is the syndrome.

Rating difficulties. Evidence was the closest call. Settled on 4: multiple large RCTs and current guideline backing, but the 2021 ACG IBS guideline itself rates low-FODMAP evidence as "very low quality" per GRADE due to blinding limitations, and placebo magnitudes in functional GI trials are large (30–40%). The mechanistic literature (Accarino, Villoria) is independently strong, which pulls the composite up. Longevity scored 1 rather than 0 because the workup catches celiac and the rare ovarian/colon cancer presentations early — indirect but real. Beauty_cumulative held at 0; no mechanism for sustained aesthetic effect once symptoms resolve.

Action choice. "Respond" over "know" or "do" because the reader presents with the symptom and needs a graduated response protocol, not a daily habit and not pure awareness. Cadence "as-needed" follows: the protocol is run when symptoms surface, not maintained continuously.

Separate-entry candidates. Low-FODMAP diet as a substance in its own right (warrants protocol-depth coverage). SIBO/IMO testing and treatment as a discrete entry. Pelvic floor dysfunction. Gut-directed hypnotherapy. Celiac disease. Each has enough breadth to stand alone and is currently compressed inside this entry.

Future links. Once the IBS, constipation, and gut microbiome entries exist, the out-of-scope section should be re-wired to cross-link them directly via related meta rather than just naming them.

Deliberately omitted. Exercise-induced bloating in endurance athletes (different mechanism, splanchnic hypoperfusion; not the typical reader's experience). Ascites and structural bloating (these belong in pathology-specific entries, and the article correctly redirects readers with palpable mass or fluid swelling to a clinic). Pregnancy-related bloating (out of scope for the protocol, since strict elimination diets in pregnancy require obstetric supervision; noted briefly under audience).